Clinical trial · Observational
Non Invasive IDentification of Gliomas With IDH1 Mutation
Non Invasive IDentification of Gliomas With IDH1 Mutation by Free Plasmatic DNA Analysis, 2-hydroxyglutarate Dosage in the Urines and 2-hydroxyglutarate Detection by Brain SPEctro-MRI: Diagnostic and Follow-up Application (IDASPE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The recurrent mutation IDH1Arg132His leads to the cellular accumulation of D-2-hydroxyglutarate (2-HG), thus representing a diagnostic marker (this change is almost specific for gliomas) and prognostic (mutated gliomas have longer survival) of interest. The main objective is to identify the patients with IDH1 mutated glioma by three complementary approaches -genetic (identification of IDH1 mutation in plasmatic DNA), biochemical (2-HG dosage in the urine of patients) and radiological (2-HG
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Invasive Diagnosis of Glioma | Glioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with IDH1 R132H or wild type IDH1/IDH2 glioma
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Inclusion Criteria * Affiliated to Health Insurance regimen (sécurité sociale) * Patient of 18 years or more * written informed consent * Glioma grade II or III histologically proven * Frozen samples available * Known status IDH1/IDH2 * Presence of a measurable residual tumor (\> 2 cm in diameter FLAIR) * Karnofsky Performance Status (KPS)\> 60 Exclusion Criteria: * Contraindication to MRI \* * The rare patients with IDH2 mutation or with non Arg132His IDH1 mutation will be excluded * Inability to provide informed consent * Patient under guardianship or deprived of liberty by court
References
Publications (1)
- DERIVEDBranzoli F, Liserre R, Deelchand DK, Poliani PL, Bielle F, Nichelli L, Sanson M, Lehericy S, Marjanska M. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy. Radiology. 2023 Sep;308(3):e223255. doi: 10.1148/radiol.223255. PMID 37668523